Welcome to our dedicated page for Ginkgo Bioworks Holdings SEC filings (Ticker: DNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Ginkgo’s financial condition, capital markets activity, governance developments, and material events related to its biological product manufacturing and cell engineering platform.
Recent DNA SEC filings include multiple Forms 8-K. These current reports cover topics such as quarterly financial results, entry into a Sales Agreement for potential at-the-market offerings of Class A common stock, and corporate governance matters, including changes in executive responsibilities and the preliminary approval of a settlement of stockholder derivative actions. Each 8-K also confirms that Ginkgo’s Class A common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol DNA.
Investors reviewing Ginkgo Bioworks’ filings can use this page to locate quarterly earnings press releases furnished on Form 8-K, agreements related to equity issuance, and descriptions of legal or governance developments. Over time, the broader filing history may also include annual reports on Form 10-K, quarterly reports on Form 10-Q, and proxy statements that discuss topics such as business segments, risk factors, and corporate governance practices.
Stock Titan enhances this information by pairing real-time updates from EDGAR with AI-powered summaries that explain the key points of lengthy filings. Instead of reading entire documents line by line, users can quickly see the main themes, then drill into the original forms for details about Ginkgo Bioworks’ cell engineering and biosecurity activities, capital structure, and other disclosed matters.
Ginkgo Bioworks Holdings, Inc. reported insider equity transactions by a senior officer. On 12/12/2025, restricted stock units vested and were converted into 1,174 and 312 shares of Class A common stock, reflecting ongoing equity compensation. After these conversions, the officer directly held 8,224 Class A shares.
On 12/15/2025, 736 Class A shares were sold at $8.886 per share to satisfy tax withholding obligations tied to the vesting of restricted stock and restricted stock units. The company’s equity incentive plans allow these mandatory “sell to cover” transactions, which are described as non‑discretionary for the officer. Following the sale, the officer directly owned 7,488 Class A shares and continued to hold restricted stock units subject to multi‑year vesting schedules beginning May 1, 2024.
Steve Coen filed a notice of proposed sale of restricted stock for the company with ticker DNA. The filing covers a planned sale of 736 Class A shares through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 12/15/2025 and an aggregate market value of $6540.02. The table lists 48523595 Class A shares outstanding.
The shares to be sold were acquired on 12/12/2025 via restricted stock vesting from the issuer as compensation. The notice also reports that in the prior three months Steve Coen sold 5609 and 1312 Class A shares on 10/01/2025 and 10/17/2025, generating gross proceeds of $84135.00 and $17907.89. By signing, the seller represents he does not know any material adverse information about the issuer’s current and prospective operations that has not been publicly disclosed and acknowledges potential federal criminal penalties for intentional misstatements.
Ginkgo Bioworks insider plans another small Class A share sale. A holder has filed a notice to sell 2,200 shares of Class A common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $20,988.00. The filing lists 48,523,595 Class A shares outstanding.
The seller, identified as Austin Che, acquired these shares through restricted stock vesting in October 2022 as compensation from the issuer. Over the past three months, the same seller reported three separate NYSE sales of 2,200 Class A shares each, with gross proceeds of $23,716.00, $33,462.00, and $18,700.00. The notice also includes a representation that the seller is not aware of undisclosed material adverse information about the company’s current or prospective operations.
Ginkgo Bioworks Holdings, Inc.: Cascade Investment, L.L.C. and William H. Gates III reported beneficial ownership of 3,621,636 Class A shares, representing 7.5% of the class. William H. Gates III may be deemed to beneficially own these shares as the sole member of Cascade. The filing date of event is 09/30/2025.
The reported amount includes 299,052 earn-out shares that vest in equal tranches if the stock trades at specified price thresholds for 20 of 30 consecutive trading days before September 16, 2026, as outlined in the merger agreement. The holders report sole voting and dispositive power over 3,621,636 shares and no shared power. The percentage is based on 48,523,595 shares outstanding as of October 31, 2025. The certification states the securities are not held to change or influence control.
Form 144 filing: A stockholder filed notice to sell up to 2,200 shares of Class A common stock through Fidelity Brokerage Services, with an aggregate market value of $18,700, on or about 11/12/2025 on the NYSE.
The shares were acquired on 10/18/2022 via restricted stock vesting from the issuer as compensation. In the past three months, the filer (Austin Che) reported sales of 2,200 shares on 09/10/2025 for gross proceeds of $23,716 and 2,200 shares on 10/08/2025 for gross proceeds of $33,462. Shares outstanding were 48,523,595.
Ginkgo Bioworks (DNA) reported a smaller third quarter with a wider loss. Total revenue was $38.8 million, led by Cell Engineering at $29.4 million and Biosecurity at $9.5 million. The company recorded a net loss of $80.8 million and basic EPS of $1.45 loss, reflecting lower revenue and ongoing operating costs.
Liquidity shifted into marketable securities during 2025: cash and cash equivalents were $111.1 million and marketable securities were $350.8 million as of September 30, 2025. Net cash used in operating activities was $123.4 million for the nine months. Stockholders’ equity was $559.8 million.
Ginkgo launched a $100.0 million at‑the‑market program on September 4, 2025 and issued 975,300 Class A shares for $9.4 million in net proceeds. The restructuring begun in 2024 continued, with $10.7 million in year‑to‑date charges and expected workforce reduction costs of $28.0–$30.0 million. An amended Google Cloud agreement reset annual minimums and included a $21.4 million shortfall accrued and a one‑time $14.0 million payment in Q4 2025. As of October 31, 2025, shares outstanding were 48,523,595 Class A, 9,066,624 Class B, and 3,000,000 Class C.
Ginkgo Bioworks (DNA) furnished an 8-K announcing it issued a press release with its financial results for the third quarter ended September 30, 2025. The press release is provided as Exhibit 99.1.
The filing, dated November 6, 2025, is an administrative disclosure under Item 2.02 (Results of Operations and Financial Condition) and includes the Inline XBRL cover page file as Exhibit 104.
Ginkgo Bioworks (DNA) filed a Form 4 for its CFO showing routine equity activity tied to RSU vesting. On 10/16/2025, restricted stock units were converted to Class A shares via code M in three tranches: 1,174 shares, 312 shares, and 1,061 shares.
On 10/17/2025, the CFO sold 1,312 shares at $13.649 per share under code S to cover tax withholding related to these vestings, as permitted by the company’s equity plans. Following the transactions, the CFO directly beneficially owned 6,738 Class A shares.
DNA filed a Form 144 notice for a proposed sale of 5,609 Class A shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of 84,135. The approximate sale date listed is 10/21/2025.
The shares were acquired via restricted stock vesting as compensation on multiple dates in 2024, including 4,062 shares on 05/01/2024 and smaller vestings thereafter, totaling the amount to be sold. The filing lists 47,089,598 shares outstanding for the class. The section on recent activity shows a prior sale of 310 shares on 08/22/2025 for gross proceeds of 3,842.79.
DNA filed a Form 144 notice for a proposed sale of 1,312 shares of Class A common stock with an aggregate market value of $17,907.89, with an approximate sale date of 10/21/2025 on the NYSE through Fidelity Brokerage Services LLC.
The shares were acquired on 10/16/2025 via restricted stock vesting as compensation. In the past three months, Steve Coen sold 310 shares for gross proceeds of $3,842.79. Shares outstanding were 47,089,598; this is a baseline figure, not the amount being offered.